AstraZeneca Lung Cancer Treatment Approved in EU
April 25 2017 - 9:13AM
Dow Jones News
By Rory Gallivan
LONDON--AstraZeneca PLC (AZN.LN) Tuesday said the European Union
has given full approval to its lung cancer treatment Tagrisso.
The European Commission has granted full marketing authorization
for Tagrisso tablets for the treatment of adult patients with
locally-advanced lung cancer, AstraZeneca said.
Shares at 1235 GMT, up 43 pence, or 0.9%, at 4,706 pence valuing
the company at 59.55 billion pounds ($64.65 billion).
Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter:
@RoryGallivan
(END) Dow Jones Newswires
April 25, 2017 08:58 ET (12:58 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
